STOCK TITAN

Evoke Pharma Inc - EVOK STOCK NEWS

Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.

About Evoke Pharma Inc.

Evoke Pharma Inc. (NASDAQ: EVOK), headquartered in Solana Beach, California, is a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for gastrointestinal (GI) disorders and diseases. With a primary focus on diabetic gastroparesis, Evoke addresses a critical unmet medical need by offering a novel, non-oral treatment option that improves patient outcomes and enhances quality of life.

Core Product: Gimoti

At the heart of Evoke Pharma's portfolio is Gimoti®, an FDA-approved nasal spray formulation of metoclopramide. Designed specifically for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults, Gimoti offers a unique solution for patients who struggle with oral medications due to delayed gastric emptying, a hallmark of gastroparesis. By bypassing the gastrointestinal tract, Gimoti ensures reliable drug absorption, addressing the core defect of the disease and providing a practical alternative to traditional oral and injectable formulations.

Market Position and Competitive Landscape

Diabetic gastroparesis is a debilitating condition affecting millions worldwide, with a disproportionate prevalence among women. Despite its widespread impact, treatment options remain limited. Metoclopramide is the only FDA-approved drug for gastroparesis in the United States, and Gimoti stands out as the sole non-oral formulation available. This positions Evoke Pharma as a key player in the GI treatment landscape, offering a differentiated product that meets the needs of a historically underserved patient population.

Innovative Approach and Strategic Partnerships

Evoke Pharma's commitment to innovation is evident in its development of Gimoti, which leverages intranasal drug delivery to overcome the challenges associated with oral medications in gastroparesis patients. The company has also established strategic partnerships, such as its collaboration with EVERSANA, to support the commercialization and market access of Gimoti. These partnerships enhance Evoke's ability to reach patients, streamline the prescription process, and ensure broad access to its groundbreaking therapy.

Real-World Evidence and Impact

Real-world data underscores the clinical and economic benefits of Gimoti. Studies have demonstrated significant reductions in emergency room visits and hospitalizations among patients treated with Gimoti compared to oral metoclopramide. Additionally, Gimoti has shown a substantial reduction in overall healthcare costs, highlighting its value to both patients and payers. These outcomes reinforce Evoke Pharma's role in improving patient care and reducing the burden on the healthcare system.

Commitment to Patients and Providers

Evoke Pharma is dedicated to addressing the challenges faced by gastroparesis patients and their healthcare providers. The company's patient assistance programs and efforts to expand pharmacy distribution networks reflect its mission to ensure that no patient goes untreated due to economic or access barriers. By prioritizing patient-centric solutions and leveraging strong clinical evidence, Evoke continues to set the standard for innovation in gastroparesis treatment.

Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) is set to release its fourth quarter and full year 2023 financial results on March 14, 2024. The company will host a conference call to discuss the results, focusing on their specialty pharmaceutical products for GI diseases, particularly Gimoti® nasal spray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) closes a $30 million public offering led by Nantahala Capital Management, with potential for an additional $22.5 million if all warrants are exercised. The company plans to use the funds for working capital, general corporate purposes, and potentially for in-licensing, acquiring, or investing in complementary businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced an underwritten public offering led by Nantahala Capital Management, raising up to $30 million for working capital and corporate purposes. The offering includes 11,029,411 shares of common stock and warrants, with a combined price per share of $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.86%
Tags
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced that its GIMOTI nasal spray has received a new U.S. patent, No. 11,813,231, listed in the FDA's Orange Book, with coverage until 2029. This adds to the previous three patents, providing enhanced patent protection for GIMOTI. The company aims to redefine gastroparesis treatment with GIMOTI, targeting diabetic gastroparesis and reducing hospitalizations. The patent listing in the Orange Book allows for easier monitoring of potential generic drugs that could infringe on GIMOTI's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide” for their commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI. This patent provides additional intellectual property protections and claims to metoclopramide being delivered intranasally. The company sees significant commercial value, especially with the rising popularity of GLP-1 agonist medications for diabetes potentially unmasking gastroparesis in larger patient groups. GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis, addressing the unpredictability of tablet absorption caused by gastroparesis symptoms. Evoke Pharma aims to continue providing patients with life-changing experiences and enhancing the commercial opportunity for GIMOTI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) reports a 38% revenue increase compared to Q2 2023 and an 88% increase year-over-year. The company experienced a seventh straight prescription fill increase since Q1 2022, with a 21% increase compared to Q2 2023 and a 95% increase year-over-year. The financial results for the third quarter ended September 30, 2023, show record net product sales of $1.6 million. The company also presented data at the ACG 2023 Annual Meeting demonstrating the superiority of its nasal spray, GIMOTI, in reducing healthcare costs for treating diabetic gastroparesis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
Rhea-AI Summary
Evoke Pharma and EVERSANA announced real-world data on the positive impact of GIMOTI nasal spray in reducing healthcare costs for patients with diabetic gastroparesis. Patients and insurers saved over $15,000 per patient in a six-month period by using GIMOTI instead of oral metoclopramide. The study showed a significant reduction in emergency department visits, hospitalizations, and office visits for patients using GIMOTI compared to oral metoclopramide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary
Evoke Pharma to present real-world healthcare utilization data on GIMOTI nasal spray at the American College of Gastroenterology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary
Evoke Pharma granted patent for GIMOTI nasal spray, expected to expire in 2029. GIMOTI demonstrates reduction in healthcare resource utilization. GIMOTI can become first-line treatment for diabetic gastroparesis. Commercially available since 2020, prescribed by over a thousand HCPs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags

FAQ

What is the current stock price of Evoke Pharma (EVOK)?

The current stock price of Evoke Pharma (EVOK) is $3.6236 as of March 3, 2025.

What is the market cap of Evoke Pharma (EVOK)?

The market cap of Evoke Pharma (EVOK) is approximately 7.1M.

What does Evoke Pharma Inc. specialize in?

Evoke Pharma specializes in developing and commercializing treatments for gastrointestinal disorders, with a focus on diabetic gastroparesis.

What is Gimoti?

Gimoti is an FDA-approved nasal spray formulation of metoclopramide designed to treat symptoms of acute and recurrent diabetic gastroparesis in adults.

How does Gimoti differ from oral treatments?

Gimoti bypasses the gastrointestinal tract, ensuring reliable drug absorption for gastroparesis patients who struggle with oral medications due to delayed gastric emptying.

What makes Evoke Pharma unique in the gastroparesis treatment market?

Evoke Pharma offers the only FDA-approved non-oral treatment for gastroparesis, addressing a critical unmet need with its innovative nasal spray, Gimoti.

What challenges does Evoke Pharma face in its market?

Evoke Pharma faces challenges such as market competition, regulatory hurdles, and ensuring broad patient access to its products.

How does Evoke Pharma support patient access to Gimoti?

Evoke Pharma collaborates with pharmacy networks and offers patient assistance programs to ensure that economic or logistical barriers do not prevent access to Gimoti.

What impact has Gimoti had on healthcare costs?

Real-world data shows that Gimoti reduces emergency room visits and hospitalizations, resulting in significant cost savings for patients and the healthcare system.

Who are Evoke Pharma's strategic partners?

Evoke Pharma partners with organizations like EVERSANA to support the commercialization and market access of Gimoti.

What is diabetic gastroparesis?

Diabetic gastroparesis is a gastrointestinal disorder where delayed stomach emptying leads to symptoms like nausea, vomiting, and abdominal pain, often complicating oral drug absorption.

How does Evoke Pharma demonstrate innovation in its field?

Evoke Pharma demonstrates innovation through its development of Gimoti, a novel nasal spray that addresses the unique challenges of treating gastroparesis.
Evoke Pharma Inc

Nasdaq:EVOK

EVOK Rankings

EVOK Stock Data

7.12M
1.42M
4.59%
17.13%
2.61%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SOLANA BEACH